U.S. antitrust agencies’ actions in the healthcare sector is raising eyebrows, and contributing to a slowdown in deals, according to several antitrust experts, in part due to the uncertainty that’s been created.
To read the entire story, you must be logged in.
Please log in now or register with us.
